Drugs / J1P3
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06456424 | Nov 2024 → Nov 2025 overdue | periprosthetic joint infection, staphylococcus aureus infection | University of Calgary | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | J1P3 | “Bacteriophage cocktail consisting of phages BP13 and J1P3” NCT06456424 ↗ |
| Route | Intravenous | “administration of phages intra-articularly on day 1 and intravenously twice daily on days 1-14” NCT06456424 ↗ |